Blue­bird gets PDU­FA date for lo­vo-cel; FDA lifts hold on Di­aMed­ica stroke tri­al

The FDA has ac­cept­ed the BLA from blue­bird bio for its gene ther­a­py lovotibeglo­gene au­totem­cel, or lo­vo-cel, de­signed to treat pa­tients with sick­le cell dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER